mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Via News Knowledge File

Sanofi

organization80% conf.·synced Aug 19, 2026

Pharmaceutical company partnered with Teva for duvakitug additional indications

22
sourced metrics
805
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
54837636507USD
Aug 18, 2026reference only
Stock Return Ytd
-6.8%
Aug 18, 2026reference only
Stock Price
44.97USD
Aug 18, 2026reference only
Price 52 Week Low
41.33USD
Aug 18, 2026reference only
Price 52 Week High
52.34USD
Aug 18, 2026reference only
Margin
-68.7percent
Apr 1, 2026source
Eps
4.97USD
Mar 3, 2026⚠ sources conflictsource
Rare Disease Experience
40years
Feb 2, 2026source
Rare Disease Commitment
40years
Feb 2, 2026source
Collaboration Revenue
5.9billion_USD
Jan 30, 2026⚠ sources conflictsource
Cash
877000000.0USD
Dec 31, 2025reference only
Total Assets
126805000000.0USD
Dec 31, 2025reference only
Gross Profit
33667000000.0USD
Dec 31, 2025reference only
Rd Expense
7842000000.0USD
Dec 31, 2025reference only
Shares Outstanding
1219427096.0shares
Dec 31, 2025reference only
Acquisition Price Per Share
15.50USD
Dec 24, 2025source
China Approvals 2025
5approvals
Dec 11, 2025source
China Drug Approvals 2025
5approvals
Dec 11, 2025source

Stated objectives

Advance Dynavax's shingles vaccine candidate (Z-1018) through clinical development

source
stated

Augment Sanofi's presence in adult immunization by combining Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach

source
stated

Provide vaccine protection across the lifespan through differentiated vaccine portfolio

source
stated

Submit global regulatory submissions for amlitelimab

source
stated

Report results from AQUA and ESTUARY phase 3 studies

source
stated

Study dupilumab in chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis in phase 3 studies

source
stated

Complete global regulatory submissions for amlitelimab

source
stated

Publish results from AQUA and ESTUARY phase 3 studies

source
stated

Present COAST 1, COAST 2, SHORE and ATLANTIS results at upcoming medical conferences

source
stated

Study dupilumab in phase 3 trials for chronic pruritus of unknown origin, chronic lichen simplex, and allergic fungal rhinosinusitis

source
stated

Relationship graph · 805 connections

Employs
237
Developed by
141
regulates
88
Competes with
72
headquartered in
61
regulated by
19
researched at
18
Owns
16
headquartered in
Paris
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com